Nasdaq · CIK 0001640266
VYGR Voyager Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Aug 20, 2025. Close $2.45 on Oct 9, 2026, +3% from the 52-week low and -54% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
VYGROct 9, 2026 · close 2.45
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Voyager Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Toby Ferguson Chief Medical Officer sell | $71k 19,000 shares | -12% | +41% from low-52% from high | |
| 29Weak | Toby Ferguson Chief Medical Officer sell | $35k 10,086 shares | -6% | +1% from low-58% from high | |
| 39Weak | Alfred Sandrock President and CEO sell | $37k 10,885 shares | -2% | +1% from low-58% from high | |
| 23Weak | Todd Alfred Carter Chief Scientific Officer sell | $14k 3,305 shares | -4% | - | |
| 23Weak | Todd Alfred Carter Chief Scientific Officer sell | $24k 5,413 shares | -6% | - | |
| 23Weak | Sandell Jacquelyn Fahey Chief Legal Officer sell | $19k 4,358 shares | -5% | - | |
| 15Weak | Todd Alfred Carter Chief Scientific Officer sell | $6,110 1,191 shares | -1% | - | |
| 26Weak | Robin Swartz COO&CBO sell | $37k 6,500 shares | -5% | - |
Transactions
The last 25 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 18, 2025 | Toby Ferguson Chief Medical Officer | SOpen-market sale Common Stock | -19,000 | $3.73 | $71k | 138,914 | Aug 20, 2025 |
| Jun 3, 2025 | Grace Colon director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 4, 2025 |
| Jun 3, 2025 | Nancy Vitale director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 4, 2025 |
| Jun 3, 2025 | George A Scangos director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 4, 2025 |
| Jun 3, 2025 | Glenn Pierce director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 4, 2025 |
| Jun 3, 2025 | Jude Onyia director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 4, 2025 |
| Jun 3, 2025 | Catherine J Mackey director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 4, 2025 |
| Jun 3, 2025 | Steven Hyman director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 4, 2025 |
| Jun 3, 2025 | Michael J Higgins director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 4, 2025 |
| Jun 3, 2025 | James A Geraghty director | AGrant or award Stock Option (Right to Buy)derivative | +24,000 | $0.00 | $0 | 24,000 | Jun 4, 2025 |
| Apr 2, 2025 | Toby Ferguson Chief Medical Officer | SOpen-market sale Common Stock | -10,086 | $3.43 | $35k | 157,914 | Apr 4, 2025 |
| Apr 2, 2025 | Alfred Sandrock President and CEO | SOpen-market sale Common Stock | -10,885 | $3.43 | $37k | 430,931 | Apr 4, 2025 |
| Feb 20, 2025 | Todd Alfred Carter Chief Scientific Officer | SOpen-market sale Common Stock | -3,305 | $4.26 | $14k | 77,718 | Feb 24, 2025 |
| Feb 21, 2025 | Sandell Jacquelyn Fahey Chief Legal Officer | AGrant or award Common Stock | +41,500 | $0.00 | $0 | 123,143 | Feb 24, 2025 |
| Feb 21, 2025 | Toby Ferguson Chief Medical Officer | AGrant or award Common Stock | +63,000 | $0.00 | $0 | 168,000 | Feb 24, 2025 |
| Feb 21, 2025 | Nathan D. Jorgensen Chief Financial Officer | AGrant or award Common Stock | +51,500 | $0.00 | $0 | 131,500 | Feb 24, 2025 |
| Feb 21, 2025 | Todd Alfred Carter Chief Scientific Officer | AGrant or award Common Stock | +46,000 | $0.00 | $0 | 123,718 | Feb 24, 2025 |
| Feb 21, 2025 | Nathan D. Jorgensen Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +103,000 | $0.00 | $0 | 103,000 | Feb 24, 2025 |
| Feb 21, 2025 | Toby Ferguson Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +126,000 | $0.00 | $0 | 126,000 | Feb 24, 2025 |
| Feb 21, 2025 | Sandell Jacquelyn Fahey Chief Legal Officer | AGrant or award Stock Option (Right to Buy)derivative | +83,000 | $0.00 | $0 | 83,000 | Feb 24, 2025 |
| Feb 21, 2025 | Todd Alfred Carter Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +92,000 | $0.00 | $0 | 92,000 | Feb 24, 2025 |
| Feb 11, 2025 | Todd Alfred Carter Chief Scientific Officer | SOpen-market sale Common Stock | -5,413 | $4.45 | $24k | 81,023 | Feb 12, 2025 |
| Feb 11, 2025 | Sandell Jacquelyn Fahey Chief Legal Officer | SOpen-market sale Common Stock | -4,358 | $4.45 | $19k | 81,643 | Feb 12, 2025 |
| Jan 14, 2025 | Todd Alfred Carter Chief Scientific Officer | SOpen-market sale Common Stock | -1,191 | $5.13 | $6,110 | 86,436 | Jan 15, 2025 |
| Dec 23, 2024 | Robin Swartz COO&CBO | SOpen-market sale Common Stock | -6,500 | $5.65 | $37k | 112,328 | Dec 26, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Todd Alfred CarterChief Scientific Officer
- Grace Colondirector
- Sandell Jacquelyn FaheyChief Legal Officer
- Toby FergusonChief Medical Officer
- James A Geraghtydirector
- Michael J Higginsdirector
- Steven Hymandirector
- Nathan D. JorgensenChief Financial Officer
- Catherine J Mackeydirector
- Jude Onyiaofficer, director
- Glenn Piercedirector
- George A Scangosdirector
- Alfred SandrockPresident and CEO
- Robin SwartzCOO&CBO
- Nancy Vitaledirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.